 info@berensoncancercenter.com
 310.623.1222
berenson header logo
  • Myeloma
    • Myeloma FAQ
    • Q&A
    • Treatments
    • Books
    • News
    • Research Projects
  • Testimonials
  • Press
  • Books
  • Dr. Berenson
    • Biography
    • Curriculum Vitae
  • Contact
berenson-fallback-featured-img

Ruxolitinib Is Under Investigation as JAK Inhibition Strategy for Multiple Myeloma

Read More
berenson-fallback-featured-img

Ruxolitinib Elicits Few Adverse Effects When Treating Multiple Myeloma

Read More
berenson-fallback-featured-img

Ruxolitinib/Selinexor Combo Is Being Evaluated for Multiple Myeloma

Read More

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

footer-logo

Multiple myeloma (active) is the most common type plasma cell cancer. However, the following are other forms of myeloma or myeloma-related:

Myeloma-Related Conditions

  • Nmultiple myeloma
  • NMGUS
  • NWaldenstrom's macroglobulinemia
  • Namyloidosis
  • Nbone cancer

James R. Berenson, MD

  • 9President & Medical Director
    Berenson Cancer Center
  • 9President & CEO
    Institute for Myeloma & Bone Cancer Research (IMBCR)
  • 9Founder & President, ONCOtherapeutics
  • 9Founder & Principal, ONCOtracker
  • Dr Berenson’s Biography
  • Curriculum Vitae

Quick Links

  • Dr. James R. Berenson
  • Resources
  • Becoming a Patient
  • Registration Form
  • Privacy Policy
  • Contact
  • Myeloma
  • Myeloma FAQ
  • Multiple Myeloma Q&A
  • Testimonials
  • Press
  • Books on Multiple Myeloma
  • Follow
  • Follow
  • Follow
  • Follow

Call Us for an Appointment

 310.623.1222
If you would like to learn more about becoming a patient at the Berenson Cancer Center, please email us:

info@berensoncancercenter.com

© BERENSON CANCER CENTER, Inc. All rights reserved.
Scroll Up